uniQure NV (QURE) News

$QURE $5.14 buy it up

QURE

$26.36 +3.36 (+14.61%)
As of Nov-23-20224:00:00 PM ET

https://stockcharts.com/h-sc/ui?s=QURE

FDA Approves UniQure's Hemgenix, First Hemophilia B Gene Therapy For Adults
BENZINGA 8:12 AM ET Nov-23-2022

UniQure N.V.'s (NASDAQ:QURE) partner CSL Limited (OTC:CSLLY) has received FDA approval for Hemgenix (etranacogene dezaparvovec-drlb), a one-time gene therapy for hemophilia B.
CSL licensed the exclusive global rights to Hemgenix from uniQure in May 2021.
UniQure has received about $500 million so far from CSL and will also be eligible to get up to an additional $1.5 billion in commercial milestone payments and royalties.
Cowen analyst Joseph Thome said that Hemgenix's price of $3.5 million is higher than the brokerage's estimated $1.9 million, but its consultants have been optimistic about the therapy's uptake, Reuters reported.
Results from the pivotal HOPE-B trial support the FDA approval, the largest gene therapy trial in hemophilia B.
Results from the study demonstrated that Hemgenix allowed patients to produce mean factor IX activity of 39% at six months and 36.7% at 24 months post-infusion.
Seven to 18 months post-infusion, the mean adjusted annualized bleeding rate (ABR) for all bleeds was reduced by 54% compared to the six-month lead-in period on factor IX prophylactic replacement therapy (4.1 to 1.9).
In addition, 94% of patients treated with Hemgenix discontinued prophylaxis and remained free of previous continuous routine prophylaxis therapy.
The FDA has already cleared two gene therapies, Zynteglo and Skysona, from Bluebird bio Inc (NASDAQ: BLUE) in August and September, respectively.

Whoops!

Insiders selling big time while biopharmcatalyst site tries to pump - noit a good sign

Profit taking time .. Good time to short this .. I want to be in for a short

QURE $9.15 high today, nice.

This thing is pretty volatile lately.

QURE Looked great hitting $9.00 today

QURE General Information

http://www.reuters.com/finance/stocks/companyProfile?rpc=66&symbol=QURE.O

Uniqure NV (QURE) Money Flow Index Nearing Key Level

http://tuckermantimes.com/uniqure-nv-qure-money-flow-index-nearing-key-level/247578/

Erratic Trading Showing Unusual Volume in Shares of Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) and uniQure N.V. (NASDAQ:QURE)

https://www.concordregister.com/erratic-trading-showing-unusual-volume-in-shares-of-concert-pharmaceuticals-inc-nasdaqcnce-and-uniqure-n-v-nasdaqqure/

uniQure N.V. NASDAQ:QURE Sees High Volatility in Session

https://aikenadvocate.com/uniqure-n-v-nasdaqqure-sees-high-volatility-in-session/290264/

uniQure N.V. (QURE) PT Set at $13.00 by Chardan Capital

https://weekherald.com/2017/07/24/uniqure-n-v-qure-pt-set-at-13-00-by-chardan-capital.html

This dog has always been a turd. Why did it run last couple days? Already see signs of rollover on today's intraday imo. $QURE

buying here

Lost all patience in this pos

Patient is a virtue.
If you know what you are doing it pays off.

That's why it's down another 3%

Trust me they are. They just don't want you to think that way.

The market does not seem to be overly impressed.

Great news out

Great newsGo QURE

uniQure N.V. (NASDAQ:QURE) announced the completion of a company-wide strateghttp://www.benchmarkmonitor.com/2016/11/17/uniqure-n-v-nasdaqqure-announced-the-completion-of-a-company-wide-strategic-review/ic review


uniQure N.V. (NASDAQ:QURE), announced the completion of a company-wide strategic review aimed at refocusing its pipeline, consolidating its manufacturing and enhancing overall execution to drive shareholder value. As a result of this initiative, the Company will prioritize programs in hemophilia B, Huntington’s disease and those associated with its landmark collaboration with Bristol-Myers Squib (BMS) in cardiovascular disease.

uniQure N.V. (NASDAQ:QURE), a Healthcare sector firm, traded 495604 shares in last trading session with closing price of $7.04 per share. Company gross margin stands at 94.90% whereas its return on investment (ROI) is -49.30%. Stock value has moved between $6.64 – 22.71 in last one year. Analyst’s mean target price for uniQure N.V. (NASDAQ:QURE) is $30.10 while analysts mean recommendation is 1.60. QURE EPS growth this year is -49.60%.

I see over 100 % upside from here. Go QURE

Not sure but panzers got blasted. Data in December so will average down here and stay put

WTF happened here today?

Adding all under 9s

QURE data will show in PPS hang on tight

QURE will double here into December

Laaaaaid back QURE love it

End of summer QURE prediction will happen

QURE run to 12+ on it watch

Panzer nailing biotechs sniper

Looking fantastic QURE

This trade turning into pure genius muhahahhaha

Looking fantastic, nice runner QURE

Just blasted some QURE ask

End of summer it hits $12
In de past few weeks way oversold ..

So much for that -- now see 15K bid @ .41.

QURE

Ended up selling @ $7.37 this afternoon. Still greatly oversold but not sure can make it over .40 today and market too volatile.

QURE

no kiddin man... ez $$$ here...

Back in QURE @ $7.01 after a period of being out. Hit all time low yesterday:



QURE

Joehoe it is time to get inn folks
Happy trading ..

Making a move today - start of a nice run? $QURE

Free Fallin

This biyitch has been all over the map today. $QURE

Posted message 177 to myself. Was meant for you. Good luck.

QURE

Yep. You never know do you. Yesterday it went back close to that level early am but didn't buy. Who knew that bios would have the best day in about 4 years. If you have been holding you are doing just fine.

Overbought now so I'll wait and get back in. Great at this level and better when it dips:



QURE

too bad... $qure is at bottom...

FWIW, sold today at $12.60. Being cautious. Supposedly they are reporting on April 4th although I don't find any announcement on the company website.

QURE

Uniqure NV (QURE) Earns “Buy” Rating from Chardan Capital

March 28th, 2016 - By Renee Johnson - 0 comments

Uniqure NV logoChardan Capital reaffirmed their buy rating on shares of Uniqure NV (NASDAQ:QURE) in a research report sent to investors on Wednesday morning, MarketBeat.com reports. They currently have a $40.00 price objective on the stock.

A number of other analysts have also recently commented on the stock. Zacks Investment Research cut shares of Uniqure NV from a buy rating to a hold rating in a research report on Wednesday, November 25th. Cowen and Company restated a buy rating on shares of Uniqure NV in a research report on Monday, November 30th. Leerink Swann restated an outperform rating and issued a $48.00 price objective on shares of Uniqure NV in a research report on Friday, January 8th. Janney Montgomery Scott started coverage on shares of Uniqure NV in a research report on Monday, November 30th. They issued a buy rating and a $40.00 price objective for the company. Finally, Piper Jaffray restated an overweight rating and issued a $35.00 price objective on shares of Uniqure NV in a research report on Wednesday, January 6th. One analyst has rated the stock with a hold rating and eleven have given a buy rating to the company. The stock has a consensus rating of Buy and an average target price of $40.36.

Uniqure NV (NASDAQ:QURE) opened at 11.95 on Wednesday. The firm’s market capitalization is $289.41 million. Uniqure NV has a one year low of $10.61 and a one year high of $36.38. The company has a 50 day moving average price of $13.92 and a 200-day moving average price of $18.07.

Several institutional investors have bought and sold shares of the company. Perceptive Advisors LLC increased its position in Uniqure NV by 40.1% in the fourth quarter. Perceptive Advisors LLC now owns 967,093 shares of the company’s stock worth $15,996,000 after buying an additional 276,824 shares in the last quarter. Eventide Asset Management LLC increased its stake in shares of Uniqure NV by 12.9% in the fourth quarter. Eventide Asset Management LLC now owns 174,900 shares of the company’s stock valued at $2,893,000 after buying an additional 20,000 shares during the period. Columbus Circle Investors increased its stake in shares of Uniqure NV by 493.7% in the fourth quarter. Columbus Circle Investors now owns 113,548 shares of the company’s stock valued at $1,878,000 after buying an additional 94,422 shares during the period. Deutsche Bank AG increased its stake in shares of Uniqure NV by 53.2% in the fourth quarter. Deutsche Bank AG now owns 112,088 shares of the company’s stock valued at $1,853,000 after buying an additional 38,943 shares during the period. Finally, Tocqueville Asset Management L.P. increased its stake in shares of Uniqure NV by 5.6% in the fourth quarter. Tocqueville Asset Management L.P. now owns 79,750 shares of the company’s stock valued at $1,319,000 after buying an additional 4,200 shares during the period.

Uniqure NV is a pharmaceutical company based in the Netherlands. It is primarily engaged in the field of gene therapy for orphan diseases. The Company is focused on patients suffering from genetic or acquired diseases by directing the expression of a therapeutic protein or restoring the expression of a missing protein through a single administration.
_________________________________________________
http://www.iramarketreport.com/uniqure-nv-qure-earns-buy-rating-from-chardan-capital/41523/

QURE